Literature DB >> 24510407

Protein F-induced immune tolerance in liver transplantation in rats.

Jianbin Zhuang1, Yijun Wang, Zhi Du, Sumei Wang.   

Abstract

Liver-specific protein F is commonly used in liver transplantation studies for its allograft immunogenicity. The objective of this study was to investigate immune tolerance induced by protein F in liver transplantation in rats. Healthy inbred male Wistar and Sprague-Dawley (SD) rats were used in this study. The transplant recipient rats were randomly divided into three groups. The SD rats transplanted with liver tissues from SD rats or Wistar rats were defined as intragraft control group (Group A) or acute reaction group (Group B), respectively. The SD rats that received thymic administration of 4 mg protein F 1 week prior to transplantation with livers from Wistar rats were defined as protein F interference group (Group C). Kamada's two-cuff technique was utilized in the liver transplantation surgeries. The postoperative general condition, transplantation survival time, pathological examination, and serum IFN-γ level (quantified by ELISA) were recorded and compared to evaluate the immune response and outcomes in the recipient rats after liver transplantation. Group A rats exhibited good postoperative condition and prolonged survival (median survival time was 92 days). In contrast, Group B rats lost body weight rapidly after liver transplantation, and died starting at day 12 (median survival time was 15 days). Compared to Group B, Group C rats showed significantly longer survival (medium survival time was 71 days). Our findings indicate that protein F is an important transplantation antigen with allograft immunogenicity, which could successfully induce immune tolerance in liver transplantation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24510407     DOI: 10.1007/s11033-014-3204-8

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  11 in total

Review 1.  Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer.

Authors:  Y Yamamoto; R B Gaynor
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

2.  Intrathymic inoculation of liver specific antigen alleviates liver transplant rejection.

Authors:  Changku Jia; Shusen Zheng; Youfa Zhu
Journal:  Chin Med Sci J       Date:  2004-03

3.  Why serum F protein is a sensitive and specific marker of liver damage in man.

Authors:  G K Grewal; D B Oliveira
Journal:  Clin Chim Acta       Date:  1990-10-31       Impact factor: 3.786

Review 4.  High-dose/activation-associated tolerance: a mechanism for allograft tolerance.

Authors:  G A Bishop; J Sun; A G Sheil; G W McCaughan
Journal:  Transplantation       Date:  1997-11-27       Impact factor: 4.939

5.  Serum F protein: a new sensitive and specific test of hepatocellular damage.

Authors:  G R Foster; R D Goldin; D B Oliveira
Journal:  Clin Chim Acta       Date:  1989-09-15       Impact factor: 3.786

6.  Functional characterization of infiltrating T lymphocytes in human hepatic allografts.

Authors:  J J Fung; A Zeevi; T E Starzl; J Demetris; S Iwatsuki; R J Duquesnoy
Journal:  Hum Immunol       Date:  1986-06       Impact factor: 2.850

7.  Induction by allogeneic extracts of liver-specific precipitating autoantibodies in the mouse.

Authors:  G Fravi; J Lindenmann
Journal:  Nature       Date:  1968-04-13       Impact factor: 49.962

8.  Effectiveness of intrathymic inoculation of soluble antigens in the induction of specific unresponsiveness to rat islet allografts without transient recipient immunosuppression.

Authors:  S F Oluwole; M X Jin; N C Chowdhury; O A Ohajekwe
Journal:  Transplantation       Date:  1994-11-27       Impact factor: 4.939

9.  The relative contribution of intrathymic inoculation of donor leukocyte subpopulations in the induction of specific tolerance.

Authors:  S F Oluwole; N C Chowdhury; M X Jin
Journal:  Cell Immunol       Date:  1994-01       Impact factor: 4.868

10.  Liver-specific F antigen in the serum of patients with liver diseases and the detection of early stage hepatocellular carcinoma.

Authors:  Y Mori; S Iwama; T Mori; S Ueda; K Iesato; H Yoshida; Y Wakashin; M Wakashin; K Okuda
Journal:  Clin Chim Acta       Date:  1987-04-30       Impact factor: 3.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.